Syndax Pharmaceuticals (SNDX) Price & Analysis

Compare

765 Followers

SNDX Stock Chart & Stats

Day’s Range― - ―

52-Week Range$8.58 - $22.50

Previous CloseN/A

Volume201.89K

Average Volume (3M)2.47M

Market Cap

$1.40B

Enterprise Value$698.84M

Total Cash (Recent Filing)$468.71M

Total Debt (Recent Filing)$1.68M

Price to Earnings (P/E)―

Beta1.62

Next Earnings

Nov 11, 2025

EPS Estimate

-0.72

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.83

Shares Outstanding86,141,860

10 Day Avg. Volume2,447,168

30 Day Avg. Volume2,471,815

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.50

Enterprise Value/Revenue8.94

Enterprise Value/Gross Profit9.29

Enterprise Value/Ebitda-2.18

Forecast

1Y Price Target

$33.60

Price Target Upside106.90% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering11

Bulls Say, Bears Say

Bulls Say

EarningsSNDX reported Q2 Revuforj revenue of $28.6MM, surpassing consensus estimates, indicating strong market performance.

Market OpportunityA positive Catalyst Watch is opened ahead of the 10/25 PDUFA in R/R mNPM1 AML, which would unlock a first-to-market opportunity ~3-4x the size of KMT2Ar.

Product PipelineRevumenib would become the first and only menin inhibitor approved in both the r/r NPM1 and KMT2A AML populations if approved.

Bears Say

Adverse EventsManagement noted that physicians are experiencing a consistent adverse event profile versus clinical trials for Revuforj.

Stock ValuationThe market continues to substantially undervalue SNDX with the stock trading at a deep discount vs. strong and only improving fundamentals.

Syndax Pharmaceuticals News

3 Best Stocks to Buy Now, 8/6/2025, According to Top Analysts

Which stocks are best to buy now? According to Top Wall Street Analysts, the three stocks listed below...

19d ago

HRMY

SNDX

Citi ups Syndax target, opens ‘upside catalyst watch’

Citi analyst Yigal Nochomovitz raised the firm’s price target on Syndax (SNDX) to $51 from $46 and keeps...

20d ago

SNDX

Syndax price target raised to $56 from $43 at BTIG

BTIG analyst Justin Zelin raised the firm’s price target on Syndax (SNDX) to $56 from $43 and keeps...

20d ago

SNDX

Syndax reports Q2 EPS (83c), consensus ($1.01)

Reports Q2 revenue $37.96M, consensus $26.64M. For the second quarter, Syndax’s (SNDX) share of the Niktimvo product contribution,...

21d ago

SNDX

Syndax options imply 9.0% move in share price post-earnings

Pre-earnings options volume in Syndax (SNDX) is 4.6x normal with calls leading puts 19:2. Implied volatility suggests the...

21d ago

SNDX

Syndax Pharmaceuticals’ Axatilimab Study: A Potential Breakthrough for IPF Treatment

Syndax Pharmaceuticals Inc. (($SNDX)) announced an update on their ongoing clinical study. Syndax Pharmaceuticals Inc. is conducting a...

3d ago

SNDX

Syndax Pharmaceuticals Faces Ongoing and Emerging Business Risks: A Closer Look at SEC Filings

Syndax Pharmaceuticals Inc. (SNDX) has disclosed a new risk, in the Regulation category. Syndax Pharmaceuticals Inc. faces significant...

19d ago

SNDX

Syndax Pharmaceuticals’ Earnings Call Highlights Robust Growth

Syndax Pharmaceuticals Inc. (($SNDX)) has held its Q2 earnings call. Read on for the main highlights of the...

20d ago

SNDX

Syndax Pharmaceuticals Reports Strong Q2 2025 Growth

Syndax Pharmaceuticals Inc. ( ($SNDX) ) has released its Q2 earnings. Here is a breakdown of the information...

21d ago

SNDX

Syndax Pharmaceuticals: Strong Performance and Growth Potential Justify Buy Rating

TD Cowen analyst Phil Nadeau has maintained their bullish stance on SNDX stock, giving a Buy rating on...

21d ago

SNDX

SNDX Earnings this Week: How Will it Perform?

Syndax Pharmaceuticals Inc. (SNDX) is scheduled to report 2nd quarter earnings on 08/04/2025, after the market closes. Regarding...

23d ago

SNDX

Syndax Pharmaceuticals’ Promising AML Study: A Closer Look at SNDX-5613

Syndax Pharmaceuticals Inc. (($SNDX)) announced an update on their ongoing clinical study. Study Overview: Syndax Pharmaceuticals Inc. is...

1M ago

SNDX

Syndax price target lowered to $35 from $37 at UBS

UBS analyst David Dai lowered the firm’s price target on Syndax (SNDX) to $35 from $37 and keeps...

1M ago

SNDX

3 ‘Strong Buy’ Russell 2000 Stocks with Triple-Digit Upside Potential

As the market continues to navigate economic uncertainty, investors are increasingly looking toward smaller companies with high growth...

1M ago

AURA

NUVB

SNDX FAQ

What was Syndax Pharmaceuticals Inc’s price range in the past 12 months?

Syndax Pharmaceuticals Inc lowest stock price was $8.58 and its highest was $22.50 in the past 12 months.

What is Syndax Pharmaceuticals Inc’s market cap?

Syndax Pharmaceuticals Inc’s market cap is $1.40B.

When is Syndax Pharmaceuticals Inc’s upcoming earnings report date?

Syndax Pharmaceuticals Inc’s upcoming earnings report date is Nov 11, 2025 which is in 78 days.

How were Syndax Pharmaceuticals Inc’s earnings last quarter?

Syndax Pharmaceuticals Inc released its earnings results on Aug 04, 2025. The company reported -$0.83 earnings per share for the quarter, beating the consensus estimate of -$1.016 by $0.186.

Is Syndax Pharmaceuticals Inc overvalued?

According to Wall Street analysts Syndax Pharmaceuticals Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Syndax Pharmaceuticals Inc pay dividends?

Syndax Pharmaceuticals Inc does not currently pay dividends.

What is Syndax Pharmaceuticals Inc’s EPS estimate?

Syndax Pharmaceuticals Inc’s EPS estimate is -0.72.

How many shares outstanding does Syndax Pharmaceuticals Inc have?

Syndax Pharmaceuticals Inc has 86,141,860 shares outstanding.

What happened to Syndax Pharmaceuticals Inc’s price movement after its last earnings report?

Syndax Pharmaceuticals Inc reported an EPS of -$0.83 in its last earnings report, beating expectations of -$1.016. Following the earnings report the stock price went up 21.098%.

Which hedge fund is a major shareholder of Syndax Pharmaceuticals Inc?

Currently, no hedge funds are holding shares in SNDX

Syndax Pharmaceuticals Stock Smart Score

Neutral

Fundamentals

Return on Equity

-113.22%

Trailing 12-Months

Asset Growth

24.99%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML); and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD). The company is also developing Entinostat. It also has collaborative research and development agreement with National Cancer Institute; a clinical trial agreement with Eastern Cooperative Oncology Group; and a license agreement with Kyowa Hakko Kirin Co., Ltd. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.Massachusetts.

Syndax Pharmaceuticals (SNDX) Earnings & Revenues

Historic Earnings Reports

SNDX Company Deck

SNDX Earnings Call

Q2 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call reflects a strong performance with significant revenue growth and strategic advancements in pipeline and market expansion. The company shows a clear path to profitability with stable operating expenses and promising future opportunities. However, there are some dependencies on regulatory approvals and expectations for increased transplant rates.View all SNDX earnings summaries

SNDX Stock 12 Month Forecast

Average Price Target

$33.60

▲(106.90% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"7":"$7","32":"$32","57":"$57","19.5":"$19.5","44.5":"$44.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":56,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$56.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":33.6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$33.60</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":17,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$17.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[7,19.5,32,44.5,57],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.98,13.52,17.06,20.6,24.14,27.68,31.22,34.76,38.3,41.839999999999996,45.379999999999995,48.92,52.459999999999994,{"y":56,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.98,11.796923076923077,13.613846153846154,15.430769230769233,17.247692307692308,19.064615384615387,20.88153846153846,22.69846153846154,24.51538461538462,26.332307692307694,28.149230769230773,29.966153846153848,31.783076923076926,{"y":33.6,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.98,10.52,11.06,11.6,12.14,12.68,13.219999999999999,13.76,14.3,14.84,15.379999999999999,15.92,16.46,{"y":17,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":22,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.55,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.89,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.98,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.7,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.22,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.17,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.64,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.01,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.82,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.98,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.82,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.98,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >